Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Clinical utility of the 70-gene MammaPrint profile in a Japanese population.

Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, van Lienen E, Inaji H, Van't Veer LJ, Kato K.

Jpn J Clin Oncol. 2010 Jun;40(6):508-12. doi: 10.1093/jjco/hyp195.

PMID:
20110242
2.

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.

3.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.

Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x.

PMID:
20094918
4.

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, van't Veer L.

Breast. 2013 Oct;22(5):682-90. doi: 10.1016/j.breast.2012.12.002.

PMID:
23347730
5.

Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.

Fisher BJ, Perera FE, Cooke AL, Opeitum A, Stitt L.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):117-23.

PMID:
9747828
6.

Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.

Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.

Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38.

PMID:
9989511
7.

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.

Gevensleben H, Göhring UJ, Büttner R, Heukamp LC, Kunz G, Dimpfl T, Jackisch C, Ortmann O, Albert US, Bender R, De Snoo F, Krijgsman O, Glas AM, Ergönenc YH, Vogel C, Dykgers A, Langwieder C, Rees M, Anzeneder T.

Int J Mol Med. 2010 Dec;26(6):837-43.

PMID:
21042777
8.

Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.

Fehm T, Maul H, Gebauer S, Scharf A, Baier P, Sohn C, Jäger W, Gebauer G.

Strahlenther Onkol. 2005 Sep;181(9):580-6.

PMID:
16170485
9.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium..

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2.

PMID:
18661261
10.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ.

Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2.

PMID:
20204499
11.

Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?

Fisher BJ, Perera FE, Cooke AL, Opeitum A, Dar AR, Venkatesan VM, Stitt L, Radwan JS.

Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):551-9.

PMID:
9231679
12.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.

Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2.

PMID:
18819002
13.

Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients.

Feng Y, Sun B, Li X, Zhang L, Niu Y, Xiao C, Ning L, Fang Z, Wang Y, Zhang L, Cheng J, Zhang W, Hao X.

Breast Cancer Res Treat. 2007 Jul;103(3):319-29. Erratum in: Breast Cancer Res Treat. 2007 May;103(1):125-7.

PMID:
17123152
14.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
15.

Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.

Kim KJ, Huh SJ, Yang JH, Park W, Nam SJ, Kim JH, Lee JH, Kang SS, Lee JE, Kang MK, Park YJ, Nam HR.

Jpn J Clin Oncol. 2005 Mar;35(3):126-33.

PMID:
15741302
16.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

17.

Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.

Gago FE, Tello OM, Diblasi AM, Ciocca DR.

J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):431-7.

PMID:
10030692
18.

MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.

Slodkowska EA, Ross JS.

Expert Rev Mol Diagn. 2009 Jul;9(5):417-22. doi: 10.1586/erm.09.32. Review.

PMID:
19580427
19.

Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.

Neri A, Marrelli D, Roviello F, De Stefano A, Guarnieri A, Pallucca E, Pinto E.

Ann Surg Oncol. 2005 Mar;12(3):246-53.

PMID:
15827817
20.

Supplemental Content

Support Center